INDICATORS ON NANOTECHNOLOGY EVENTS YOU SHOULD KNOW

One of the first lead compounds tested in vitro and in vivo in my lab has finished stage I-IIb clinical trials, as the globe’s initially pan-Bcl-two/Bcl-xL/Mcl-1 inhibitor entered clinic trials. One more XIAP inhibitor is also in medical trials. Molecular therapy targeting cancer and cancer stem cells, by way of novel nanovectors and rational dr